FDA US Agent services, backed by former regulators and global expertise

Published: 10-Jun-2026
Regulatory

If you’re a medical device company based outside the US, appointing a US Agent is more than just an FDA requirement — it’s a critical part of your regulatory success

If you need a trusted US Agent backed by regulatory experts, NSF can keep your US market entry on track

If you’re a medical device company based outside the US, appointing a US Agent is more than just an FDA requirement — it’s a critical part of your regulatory success.

But not all agents are created equal.

NSF provides US Agent services backed by regulatory expertise, so you’re not just meeting the requirement but also working with someone who understands what’s at stake.

Click here to read the full article

See more

You may also like

Regulatory

NHS, MHRA and Medicines UK launch Project Revive to tackle medicine shortages

Read more
NHS England, the MHRA and Medicines UK have launched Project Revive, a collaborative pilot designed to address critical medicines shortages by fast-tracking dormant MHRA-approved licences and creating dedicated NHS purchasing arrangements to improve long-term supply resilience

Trending Articles

  1. Next expansion milestone achieved: SCHOTT Pharma opens production facility in Serbia to strengthen competitiveness in Europe After a double-digit million euro investment and less than 1.5 years of construction, SCHOTT Pharma opens new manufacturing site in Jagodina, Serbia. Production capacity to meet European market demand for pharmaceutical ampoules. Facility brings around 180 new jobs to the region
  2. You need to be a subscriber to read this article.
    Click here to find out more.
    NICE approval is not enough: why the UK’s next medicines challenge is operational delivery A medicine is not truly accessible until it can be manufactured, procured, stocked, prescribed, dispensed and delivered reliably. That distinction is becoming increasingly important, says Varun Cruz, founder of NEUVIOR
  3. FDA Form 483 flags falsified records and live bird infestation at Dabur India OTC plant A FDA inspection report issued in January 2026 has revealed widespread CGMP failures at Dabur India's Dadra and Nagar Haveli facility, including manipulated microbiology data, fraudulent equipment logs and unsanitary storage conditions
  4. Safety in pharmaceutical manufacturing: why a trusted partner makes all the difference By taking a three-tiered approach to protecting patients and personnel and ensuring plant compliance, GEA adopts a consultative approach to helping its customers navigate the responsibilities of pharmaceutical manufacturing safety with confidence
  5. AMR Bio urges US policymakers to make infection prevention a core AMR strategy Submitted ahead of PACCARB's 27th public meeting, AMR Bio's recommendations call for topical antimicrobials such as MRSA-active XF-73 to receive federal support alongside conventional antibiotic development

Upcoming event

BIO International Convention

22–25 June 2026 | Convention | Boston, US See all

You may also like

Regulatory

NHS, MHRA and Medicines UK launch Project Revive to tackle medicine shortages

NHS England, the MHRA and Medicines UK have launched Project Revive, a collaborative pilot designed to address critical medicines shortages by fast-tracking dormant MHRA-approved licences and creating dedicated NHS purchasing arrangements to improve long-term supply resilience
Regulatory

UK trials subscription scheme to lure pharma into drug development

The initiative pays pharmaceuticals upfront for access to drugs based on their usefulness to the NHS
Regulatory

Patients could lose out on life-saving treatments

Limited access to novel therapies could hinder effective personalised cancer treatment in the UK, says GlobalData
Media

Supplies of medicines could be disrupted when UK leaves EU

Patients could find supplies of medicines will be disrupted when the UK leaves the EU, according to the Brexit Health Alliance in a briefing paper published 29 January, which is calling on both sides to put patients first
Regulatory

AMR Bio urges US policymakers to make infection prevention a core AMR strategy

Submitted ahead of PACCARB's 27th public meeting, AMR Bio's recommendations call for topical antimicrobials such as MRSA-active XF-73 to receive federal support alongside conventional antibiotic development
Manufacturing

Safety in pharmaceutical manufacturing: why a trusted partner makes all the difference

By taking a three-tiered approach to protecting patients and personnel and ensuring plant compliance, GEA adopts a consultative approach to helping its customers navigate the responsibilities of pharmaceutical manufacturing safety with confidence
You need to be a subscriber to read this article.
Click here to find out more.
Regulatory

NICE approval is not enough: why the UK’s next medicines challenge is operational delivery

A medicine is not truly accessible until it can be manufactured, procured, stocked, prescribed, dispensed and delivered reliably. That distinction is becoming increasingly important, says Varun Cruz, founder of NEUVIOR
Subscribe now